ClinicalTrials.gg

Program

LP-98

A development code. Also written as “LP-98 injection”, “Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.” and “LP-98 20 mg”.

Its studies are mostly in Acquired Immunodeficiency Syndrome, led by Shanxi Kangbao Biological Product.

Furthest: phase 2, since Aug 15, 20243 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanxi Kangbao Biological Product31 open or runningphase 2since Aug 15, 2024Jun 27, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2023First study: phase 1 study in Acquired Immunodeficiency SyndromeFirst studyNCT05933824 · 36 enrolled · China
  2. Aug 15, 2024Phase 2 study in Acquired Immunodeficiency SyndromeNCT06560489 · 40 enrolled · China
  3. Feb 5, 2026Phase 2 study in HIVNCT07433387 · 30 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07433387HIV · China2RecruitingJul 10, 202630
NCT06560489Acquired Immunodeficiency Syndrome · China2CompletedJan 10, 202540
NCT05933824Acquired Immunodeficiency Syndrome · China1CompletedApr 12, 202436

How it is read

Names in the registry

  • “LP-98 injection”, 1 entry
  • “Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.”, 1 entry
  • “LP-98 20 mg”, 1 entry
  • “LP-98 40 mg”, 1 entry
  • “LP-98 80 mg”, 1 entry

Codes read as this program: LP98.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.